Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.
Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
Verge has pioneered the industry's most advanced all-in-human, artificial intelligence powered drug discovery platform to unlock new drugs at scale for the biggest medical challenges of our time.
Verge was born from the convergence of multiple technological forces, including human genomics, machine learning, biological engineering, and translational medicine, that are enabling us to decipher biology. Instead of using animal or cell models, we have built one of the world's largest proprietary multi-omics databases directly from human tissue. We use machine learning to map the complex causes of disease and develop those insights into proprietary drug candidates on our internal biology and chemistry platforms.
Our first drug VRG50635, a small molecule inhibitor of PIKfyve, has entered the clinic for amyotrophic lateral sclerosis (ALS). It was discovered by CONVERGE®, Verge’s all-in-human, AI-powered platform, moving from research to clinic in just four years. We are working on a dozen breakthrough opportunities on Parkinson's Disease, Frontotemporal Dementia, and other devastating diseases with no effective treatments to date.
